Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide.
Future Oncol
; 10(6): 985-93, 2014 May.
Article
em En
| MEDLINE
| ID: mdl-24941984
ABSTRACT
AIM:
To identify factors predicting primary resistance to new-generation hormonal agents (NHAs), abiraterone acetate and enzalutamide in patients with castration-resistant prostate cancer (CRPC). PATIENTS &METHODS:
Our hospital has conducted two successive named patient NHA programs. A total of 57 patients with progressive CRPC previously treated with first-line docetaxel-based chemotherapy received standard NHA doses abiraterone acetate 1000 mg once-daily combined with prednisone (5 mg twice daily) or enzalutamide 160 mg once-daily. Patients, who were assessed monthly to check their hematological parameters and prostate-specific antigen (PSA) levels, also underwent imaging investigations every 3-4 months. In total, 24 variables were assessed as potential predictors of primary NHA resistance.RESULTS:
Univariate analysis indicated that baseline pain and lactate dehydrogenase levels, and PSA levels after 1 month's treatment were predictive of primary NHA resistance. Only the predictive value of PSA levels after 1 month of treatment was confirmed at multivariate analysis. This factor strongly predicted progression-free and overall survival.CONCLUSION:
RESULTS suggest the use of a simple and rapid method of identifying patients with primary resistance to NHAs patients not achieving a ≥ 50% reduction in PSA levels within the first treatment month should undergo intensive investigations to verify whether they have primary resistance to NHAs.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Feniltioidantoína
/
Neoplasias da Próstata
/
Antígeno Prostático Específico
/
Resistencia a Medicamentos Antineoplásicos
/
Androstadienos
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2014
Tipo de documento:
Article
País de afiliação:
Itália